Healthcare company rolls out wellness initiative in Saudi Arabia

Workplace wellness is instrumental for a balanced and productive work place. (Supplied)
Updated 10 October 2019

Healthcare company rolls out wellness initiative in Saudi Arabia

  • The initiative is rolled-out in association with MySaudiWellness, an integrated digital health and wellness provider
  • The aim of the initiative is to build a culture of a healthy and active workforce focused on adopting healthy habits

Johnson & Johnson the multinational healthcare company launched its first series of monthly employee wellness initiatives in Saudi Arabia.

The initiative is rolled-out in association with MySaudiWellness, an integrated digital health and wellness provider offering a range of services and digital health platform that provide a multidimensional view of the health data of employees and their families.

The aim of the initiative is to build a culture of a healthy and active workforce focused on adopting healthy habits, with a balanced lifestyle promoting physical activity and
mental wellness.

Workplace wellness is instrumental for a balanced and productive work place. As a healthcare company Johnson & Johnson are committed to having the healthiest employees and motivate them to be at their personal best when it comes to their health and well-being.

For 2019, the key themes of the wellness initiatives will focus on healthy eating, sleep habits, stress management as well as ergonomics and improving posture.

The series was debuted by the CEO of My Saudi Wellness Samer Al-Hashim with an interactive session by Scott Ellis an experienced lifestyle coach and health expert addressing modern-day dieting myths and healthy behaviors around food.”


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.